Thyrotropinoma with Graves’ disease detected by the fusion of indium-111 octreotide scintigraphy and pituitary magnetic resonance imaging
暂无分享,去创建一个
A. Taşlıpınar | E. Bolu | N. Arslan | K. Okuyucu | E. Alagoz | Metin Deveci
[1] D. Huglo,et al. Coexistence of Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma and Graves' Hyperthyroidism , 2013, European Thyroid Journal.
[2] D. Aksoy,et al. Thyrotropinoma and multinodular goiter: A diagnostic challenge for hyperthyroidism , 2013, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
[3] R. Gadiraju,et al. Diffuse Lung Uptake of 111In Octreotide from Chronic Emphysema* , 2013, The Journal of Nuclear Medicine Technology.
[4] P. Beck‐Peccoz,et al. 2013 European Thyroid Association Guidelines for the Diagnosis and Treatment of Thyrotropin-Secreting Pituitary Tumors , 2013, European Thyroid Journal.
[5] F. Minuto,et al. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5 , 2011, Pituitary.
[6] P. Beck‐Peccoz,et al. Pituitary tumours: TSH-secreting adenomas. , 2009, Best practice & research. Clinical endocrinology & metabolism.
[7] M. Losa,et al. Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy. , 2008, Minerva endocrinologica.
[8] N. Takasu,et al. Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman. , 1985, Acta endocrinologica.
[9] S. Yamada,et al. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. , 2015, Endocrine journal.